Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Centre Oscar Lambret
Merck Sharp & Dohme LLC
University of Southern California
I-Mab Biopharma US Limited
AstraZeneca
ALX Oncology Inc.
AstraZeneca
Servier
Sun Yat-sen University
Novartis
Daiichi Sankyo
UNICANCER
AllVascular
Novartis
National Cancer Institute, Naples
Fudan University
Imugene Limited
Providence Health & Services
Centre Hospitalier Universitaire de Besancon
Genentech, Inc.
Tyme, Inc
Federation Francophone de Cancerologie Digestive
OHSU Knight Cancer Institute
ETOP IBCSG Partners Foundation
Harbin Medical University
UNICANCER
National Cancer Institute, Naples
Amgen
Sun Yat-sen University
H. Lee Moffitt Cancer Center and Research Institute
Fudan University
Universitätsklinikum Hamburg-Eppendorf
Fudan University
EMD Serono
SCRI Development Innovations, LLC
Fox Chase Cancer Center
University of Kansas Medical Center
Odonate Therapeutics, Inc.
AIO-Studien-gGmbH
Brown University
Novartis
Memorial Sloan Kettering Cancer Center
Odense University Hospital
R-Pharm
AbbVie
Herlev Hospital
University of Florida
ChineseAMS